Announces Participation At Upcoming Investor Conferences

Speakers: Scott Braunstein, M. D., Chief Executive Officer, and Steven Pfanstiel, Chief Financial Officer. Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies. Jun 16, 2022 3:00 pm PDT. All forward-looking statements contained in this press release speak only as of the date on which they were made. Rare & Orphan Disease Summit and invites investors to participate via webcast and in one-on-one meetings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Casma Therapeutics, Inc. 857-777-4248. Details of the events are as follows: - Oppenheimer's 32 nd Annual Virtual Healthcare Conference: The company will participate in a fireside chat on Tuesday, March 15, 2022, at 4:00 p. m. ET and will participate in one-on-one meetings during the conference. Savara Inc. at JMP Securities 2018 Life Sciences Conference. Oppenheimer rare and orphan disease summit 2017. Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Oppenheimer rare and orphan disease summit il
Oppenheimer rare and orphan disease summit park
Oppenheimer rare and orphan disease summit illinois
Who are the oppenheimers
Oppenheimer rare and orphan disease summit 2017
Oppenheimer rare and orphan disease summit 2022

Oppenheimer Rare And Orphan Disease Summit Il

Oppenheimer 31st Annual Healthcare Conference. CEO Update: Celebrating Rare Disease Day - A Conversation with MAGIC Foundation Co-Founder. The platform, comprised of a family of over 160 engineered peptides, leverages one billion years of evolution that has enabled the human astrovirus to inhibit components of the innate immune system. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. About Inversago Pharma. About 9 Meters Biopharma. Oppenheimer rare and orphan disease summit 2022. BofA Securities 2021 Virtual Health Care Conference. Further raise the innovation-bar for diabetes treatment. Lumos Pharma to Present at the H. C. Wainwright BIOCONNECT Virtual Conference. Events & Presentations. For more information, please visit Norfolk, VA, February 16, 2021 – ReAlta Life Sciences, Inc. ("ReAlta"), a company addressing life-threatening diseases through harnessing the More.

Details are as follows: Date: Friday, May 21, 2021. Regulus maintains its corporate headquarters in San Diego, CA. Posters & Publications. SAN DIEGO, May 14, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 11:35 A. Oppenheimer rare and orphan disease summit illinois. M. ET.

Oppenheimer Rare And Orphan Disease Summit Park

Live webcasts of the presentations (where applicable) will be on the Investors page of the Company's website at. D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a. m. ET. Executive Vice President, CFO. Piper Sandler 33rd Annual Virtual Healthcare Conference.

The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Dr. Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit. Dionne will continue to serve on the Board of Directors. For more information about Oppenheimer's Rare & Orphan Disease Summit, please refer to the conference website. Please contact your representative at Oppenheimer & Co. to schedule a virtual one-on-one meeting with 9 Meters during the respective conference.

Oppenheimer Rare And Orphan Disease Summit Illinois

The Retina Society 55th Annual Scientific Meeting. Savara Inc. Corporate Update Call. Rezolute Corporate Update Call. A live webcast of the presentation will be available on the investor relations section of the Company's website at. Norfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted More. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U. S. Securities and Exchange Commission ("SEC"). Vanda Pharmaceuticals Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Oppenheimer Rare and Orphan Disease Summit. Scientific Advisory Board. Webcast: * a replay will be available following the presentation for 90 days. For more information, please visit Contacts. Time:||12:00 p. m. ET|.

2019 BIO Investor Forum Conference. That is, maintaining the same high standards throughout the entire product development process, and never losing sight of our ultimate goal–improving patients' lives. Courteney Backstrom. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.

Who Are The Oppenheimers

For more information, visit Forward‐Looking Statements. Skip to main navigation. Site - Shareholder Tools. WORCHESTER, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M. D., President and Chief Executive Officer, will participate in three virtual investor conferences in March 2022. A webcast of the presentation will be available on the investor page of Harmony's website at About Harmony Biosciences. Wednesday, May 19, 2021, 4:50 p. ET. View source version on. D., president and chief executive officer, will participate in multiple conferences in May. Harmony Biosciences to Present at the Oppenheimer Rare and Orphan Disease Summit. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. Format: 40-minute live virtual presentation. Virtual Pediatric Endocrine Society 2020 Annual Meeting.

March 15 – 20, 2022AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. The slide deck will be posted following the presentation. ET and will remain available on the News & Events page of the Investor Relations section of Mustang's website,, for approximately 30 days after the meeting. Please note that any opinions, estimates or forecasts regarding Vanda Pharmaceuticals Inc. 's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vanda Pharmaceuticals Inc. or its management. D., President and Chief Executive Officer, Gregory K. Chow, Executive Vice President and Chief Financial Officer and Jotin Marango, M. D., Ph.

Oppenheimer Rare And Orphan Disease Summit 2017

Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. November 11th - 2021The Society of Neuroscience Annual Meeting. Previously, he founded and ran the Novartis global Pharmacogenetics department, one of the industry leaders. Source: Aptose Biosciences, Inc. Committee Composition. Savara at Bank of America Merrill Lynch 2018 Healthcare Conference. For more information, please visit Contact for Investors and Media. Savara Inc. at Jefferies 2017 Global Healthcare Conference. Nov 2 – Nov 5, 2022. Piper Sandler Lung Day. Sep 15 – Sep 17, 2022.

Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. Friday, May 21, 2021 (1x1 meetings only). Marinus Pharmaceuticals, Inc. 484-253-6792. Evercore ISI HealthCONx Conference. Prior to that he worked for many years at the National Institute of Mental Health and the National Human Genome Research Institute, where he did pioneering work in gene mapping. Autophagy is a conserved cellular process that contributes to overall organismal health, but when autophagy is perturbed, inefficient autophagic flux contributes to numerous diseases. SOURCE Regulus Therapeutics Inc. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. February 7 – 1118TH ANNUAL WORLDSYMPOSIUM ON LYSOSOMAL DISEASE RESEARCH. Released September 16, 2019. A replay of the webcast will be archived for 30 days following the presentation date.

Oppenheimer Rare And Orphan Disease Summit 2022

Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). Media Contact: Source: Investor attendees will have the opportunity to meet with the Aptose management team to discuss key therapeutic programs, strategic direction and recent corporate updates. SOURCE: 9 Meters Biopharma.

Please see additional details below: Oppenheimer's Rare & Orphan Disease Summit. MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. Mustang Bio, Inc. (781) 652-4500. Date||Title and Summary||Additional Format|. Jefferies 2017 London Healthcare Conference.